OA11871A - Novel pharmaceutical. - Google Patents
Novel pharmaceutical. Download PDFInfo
- Publication number
- OA11871A OA11871A OA1200100275A OA1200100275A OA11871A OA 11871 A OA11871 A OA 11871A OA 1200100275 A OA1200100275 A OA 1200100275A OA 1200100275 A OA1200100275 A OA 1200100275A OA 11871 A OA11871 A OA 11871A
- Authority
- OA
- OAPI
- Prior art keywords
- polymorph
- provides
- compound
- polymorph according
- containing peaks
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Steroid Compounds (AREA)
Claims (13)
11 CLAIMS 118 7 1
1. A polymorphie form of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid sait (the "Polymorph") characterised in that it: (i) provides an infra red spectrum containing peaks at 1360, 1326, 1241, 714 and669 cm'l; and/or (ii) provides a Raman spectrum containing peaks at 1581, 768, 670, 271 and 226cm" 1; and/or (iii) provides a solid-state nuclear magnetic résonance spectrum containing peaksat Chemical shifts substantially as set out in Table I; and/or (iv) provides an X-ray powder diffraction (XRPD) pattern containing peakssubstantially as set out in Table IL
2. A Polymorph according to claim 1, which provides an infra red spectrumsubstantially in accordance with Figure I.
3. A Polymorph according to claim 1 or claim 2, which provides a Ramanspectrum substantially in accordance with Figure II.
4. A Polymorph according to any on of daims 1 to 3, which provides a solid-state nuclear magnetic résonance spectrum substantially in accordance with Figure III.
5. A Polymorph according to any one of daims 1 to 4, which provides an X-raypowder diffraction (XRPD) pattern substantially in accordance with Figure IV.
6. A Polymorph according to any one of daims 1 to 5, in isolated form.
7. A Polymorph according to any one of daims 1 to 6, in pure form.
8. A Polymorph according to any one of daims 1 to 7, in crystalline form.
9. A process for preparing a Polymorph according to daim 1, characterised inthat: (a) a slurry of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 2,4-dione, maleic acid sait (hereinafter also referred to as "Compound (1)" or the"Original Polymorph") in aqueous éthanol containing up to about 2.5% w/v water, is 12 118 7 1 heated for an extended period of time; after which time the Polymorph is recoveredfrom the denatured éthanol; or (b) Compound (I) is admixed with denatured éthanol, heated to an elevatedtempérature, over an extended period of time, after which time the Polymorph isrecovered from the solvent; or (c) Compound (I) in denatured éthanol containing up to 2.5% w/v water at 55°C isseeded with the Polymorph then cooled to a température in the range of from 20°C to25°C to provide the Polymorph; the Polymorph is then recovered from the solvent..
10. A pharmaceutical composition comprising an effective, non-toxic amount of aPolymorph according to claim 1 and a pharmaceutically acceptable carrier therefor.
11. A Polymorph according to claim 1, for use as an active therapeutic substance.
12. A Polymorph according to claim 1, for use in the treatment and/or prophylaxisof diabètes mellitus, conditions associated with diabètes mellitus and certaincomplications thereof.
13. The use of Polymorph for the manufacture of a médicament for the treatmentand/or prophylaxis of diabètes mellitus, conditions associated with diabètes mellitusand certain complications thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9909472.4A GB9909472D0 (en) | 1999-04-23 | 1999-04-23 | Novel compounds |
| GBGB9912197.2A GB9912197D0 (en) | 1999-05-25 | 1999-05-25 | Novel pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11871A true OA11871A (en) | 2006-03-27 |
Family
ID=26315460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200100275A OA11871A (en) | 1999-04-23 | 2000-04-19 | Novel pharmaceutical. |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6815457B1 (fr) |
| EP (3) | EP1284268B1 (fr) |
| JP (1) | JP2002543075A (fr) |
| KR (1) | KR100744359B1 (fr) |
| CN (1) | CN1208335C (fr) |
| AP (1) | AP1495A (fr) |
| AR (2) | AR023568A1 (fr) |
| AT (2) | ATE247653T1 (fr) |
| AU (1) | AU765498B2 (fr) |
| BG (1) | BG65427B1 (fr) |
| BR (1) | BR0009934A (fr) |
| CA (1) | CA2370258A1 (fr) |
| CO (1) | CO5170424A1 (fr) |
| CY (1) | CY1107238T1 (fr) |
| CZ (1) | CZ20013799A3 (fr) |
| DE (2) | DE60037602T2 (fr) |
| DK (2) | DK1284268T3 (fr) |
| DZ (1) | DZ3155A1 (fr) |
| EA (1) | EA004534B1 (fr) |
| ES (2) | ES2298327T3 (fr) |
| HK (2) | HK1045154B (fr) |
| HR (1) | HRP20010773B1 (fr) |
| HU (1) | HUP0200929A3 (fr) |
| IL (1) | IL146110A0 (fr) |
| MA (1) | MA26785A1 (fr) |
| MX (1) | MXPA01010820A (fr) |
| MY (1) | MY128007A (fr) |
| NO (1) | NO320589B1 (fr) |
| NZ (1) | NZ515163A (fr) |
| OA (1) | OA11871A (fr) |
| PE (1) | PE20010040A1 (fr) |
| PL (1) | PL351686A1 (fr) |
| PT (2) | PT1173434E (fr) |
| RS (1) | RS50114B (fr) |
| SK (1) | SK286423B6 (fr) |
| TR (1) | TR200103061T2 (fr) |
| TW (1) | TW591027B (fr) |
| UA (1) | UA67843C2 (fr) |
| UY (1) | UY26120A1 (fr) |
| WO (1) | WO2000064892A2 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664278B2 (en) | 1997-12-16 | 2003-12-16 | Smithkline Beecham P.L.C. | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| US20020137940A1 (en) * | 1997-12-16 | 2002-09-26 | Smithkline Beecham P.L.C. | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
| GB9726568D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| BR0009934A (pt) | 1999-04-23 | 2002-06-04 | Smithkline Beecham Plc | Produto farmacêutico |
| PL351684A1 (en) | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt |
| GB0006133D0 (en) | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
| US7241895B2 (en) * | 2000-09-26 | 2007-07-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| NZ525498A (en) * | 2000-09-26 | 2004-11-26 | Reddys Lab Ltd Dr | Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| WO2003050116A1 (fr) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | Sel d'acide 10-camphorsulphonique de 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione et son utilisation contre le diabete sucre |
| GB0130511D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| AU2002352479A1 (en) * | 2001-12-20 | 2003-07-09 | Smithkline Beecham Plc | 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus |
| GB0307259D0 (en) * | 2003-03-28 | 2003-05-07 | Glaxo Group Ltd | Process |
| EP1468997A3 (fr) * | 2003-04-18 | 2004-11-03 | CHEMI S.p.A. | Formes polymorphes de maléate de rosiglitatone |
| GB2405403A (en) * | 2003-08-29 | 2005-03-02 | Cipla Ltd | Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base |
| WO2005073227A2 (fr) * | 2004-01-28 | 2005-08-11 | Usv Limited | Procede de preparation de maleate de 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione |
| ITMI20041537A1 (it) * | 2004-07-28 | 2004-10-28 | Chemi Spa | Nuova forma polimorfa del rosiglitazone maleato |
| CZ298424B6 (cs) * | 2005-05-24 | 2007-09-26 | Zentiva, A. S. | Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel |
| US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| US20090076093A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched rosiglitazone |
| EP2184055A1 (fr) | 2008-11-07 | 2010-05-12 | LEK Pharmaceuticals d.d. | Procédé de préparation de formes galéniques solides de maléate de rosiglitazone |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
| US6288095B1 (en) | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
| GB9124513D0 (en) | 1991-11-19 | 1992-01-08 | Smithkline Beecham Plc | Novel process |
| US5741803A (en) | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
| GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| DE4404198A1 (de) | 1994-02-10 | 1995-08-17 | Henkel Kgaa | 2-Fluor-6-nitroaniline |
| SG47100A1 (en) | 1994-02-10 | 1998-03-20 | Smithkline Beecham Plc | Use of insulin sensitisers for treating renal diseases |
| US20010044458A1 (en) * | 1994-02-10 | 2001-11-22 | Smithkline Beechamp P.L.C. | Use of insulin sensitisers for treating renal diseases |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| GB9711683D0 (en) | 1997-06-05 | 1997-08-06 | Smithkline Beecham Plc | Composition |
| PL198018B1 (pl) | 1997-06-18 | 2008-05-30 | Smithkline Beecham Plc | Kompozycja farmaceutyczna przeciwcukrzycowa zawierająca sulfonylomocznik i tiazolidynodion i jej zastosowanie |
| US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
| EP0975343A1 (fr) | 1997-06-18 | 2000-02-02 | Smithkline Beecham Plc | Traitement du diabete a l'aide de thiazolidinedione et d'un inhibiteur des alpha-glucosidases |
| US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
| GB9712866D0 (en) | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
| JP2002504137A (ja) | 1997-06-18 | 2002-02-05 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | チアゾリジンジオンおよびメトホルミンを用いる糖尿病の治療 |
| US20020028768A1 (en) * | 1997-06-18 | 2002-03-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with rosiglitazone and insulin |
| US20020045649A1 (en) * | 1997-07-18 | 2002-04-18 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione and sulphonylurea |
| US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
| GB9726568D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB9726566D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB9726563D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| US20020137940A1 (en) | 1997-12-16 | 2002-09-26 | Smithkline Beecham P.L.C. | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
| EP1175418A2 (fr) | 1999-04-23 | 2002-01-30 | Smithkline Beecham Plc | Nouvel agent pharmaceutique |
| BR0009934A (pt) | 1999-04-23 | 2002-06-04 | Smithkline Beecham Plc | Produto farmacêutico |
| PL351684A1 (en) | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt |
| NZ525498A (en) | 2000-09-26 | 2004-11-26 | Reddys Lab Ltd Dr | Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
-
2000
- 2000-04-19 BR BR0009934-1A patent/BR0009934A/pt not_active Application Discontinuation
- 2000-04-19 PL PL00351686A patent/PL351686A1/xx not_active Application Discontinuation
- 2000-04-19 CO CO00028932A patent/CO5170424A1/es not_active Application Discontinuation
- 2000-04-19 KR KR1020017013557A patent/KR100744359B1/ko not_active IP Right Cessation
- 2000-04-19 PT PT00920889T patent/PT1173434E/pt unknown
- 2000-04-19 HU HU0200929A patent/HUP0200929A3/hu not_active IP Right Cessation
- 2000-04-19 DK DK02080320T patent/DK1284268T3/da active
- 2000-04-19 UA UA2001117938A patent/UA67843C2/uk unknown
- 2000-04-19 DK DK00920889T patent/DK1173434T3/da active
- 2000-04-19 WO PCT/GB2000/001514 patent/WO2000064892A2/fr not_active Application Discontinuation
- 2000-04-19 AR ARP000101870A patent/AR023568A1/es unknown
- 2000-04-19 DZ DZ003155A patent/DZ3155A1/fr active
- 2000-04-19 RS YUP-752/01A patent/RS50114B/sr unknown
- 2000-04-19 PT PT02080320T patent/PT1284268E/pt unknown
- 2000-04-19 ES ES02080320T patent/ES2298327T3/es not_active Expired - Lifetime
- 2000-04-19 JP JP2000614244A patent/JP2002543075A/ja active Pending
- 2000-04-19 MX MXPA01010820A patent/MXPA01010820A/es unknown
- 2000-04-19 TR TR2001/03061T patent/TR200103061T2/xx unknown
- 2000-04-19 EP EP02080320A patent/EP1284268B1/fr not_active Expired - Lifetime
- 2000-04-19 AR ARP000101865A patent/AR023564A1/es unknown
- 2000-04-19 OA OA1200100275A patent/OA11871A/en unknown
- 2000-04-19 SK SK1491-2001A patent/SK286423B6/sk not_active IP Right Cessation
- 2000-04-19 AU AU41306/00A patent/AU765498B2/en not_active Ceased
- 2000-04-19 US US10/030,323 patent/US6815457B1/en not_active Expired - Fee Related
- 2000-04-19 EP EP00920889A patent/EP1173434B1/fr not_active Expired - Lifetime
- 2000-04-19 NZ NZ515163A patent/NZ515163A/xx unknown
- 2000-04-19 CN CNB008090572A patent/CN1208335C/zh not_active Expired - Fee Related
- 2000-04-19 CA CA002370258A patent/CA2370258A1/fr not_active Abandoned
- 2000-04-19 PE PE2000000364A patent/PE20010040A1/es not_active Application Discontinuation
- 2000-04-19 EA EA200101119A patent/EA004534B1/ru not_active IP Right Cessation
- 2000-04-19 EP EP07150378A patent/EP1903043A1/fr not_active Withdrawn
- 2000-04-19 AP APAP/P/2001/002333A patent/AP1495A/en active
- 2000-04-19 IL IL14611000A patent/IL146110A0/xx unknown
- 2000-04-19 AT AT00920889T patent/ATE247653T1/de not_active IP Right Cessation
- 2000-04-19 AT AT02080320T patent/ATE382046T1/de not_active IP Right Cessation
- 2000-04-19 DE DE60037602T patent/DE60037602T2/de not_active Expired - Fee Related
- 2000-04-19 DE DE60004658T patent/DE60004658T2/de not_active Expired - Fee Related
- 2000-04-19 CZ CZ20013799A patent/CZ20013799A3/cs unknown
- 2000-04-19 ES ES00920889T patent/ES2204557T3/es not_active Expired - Lifetime
- 2000-04-21 MY MYPI20001707A patent/MY128007A/en unknown
- 2000-04-24 TW TW089107633A patent/TW591027B/zh not_active IP Right Cessation
- 2000-04-24 UY UY26120A patent/UY26120A1/es not_active Application Discontinuation
-
2001
- 2001-10-22 MA MA26377A patent/MA26785A1/fr unknown
- 2001-10-22 NO NO20015149A patent/NO320589B1/no unknown
- 2001-10-22 HR HR20010773A patent/HRP20010773B1/xx not_active IP Right Cessation
- 2001-11-20 BG BG106119A patent/BG65427B1/bg unknown
-
2002
- 2002-06-28 HK HK02104882.1A patent/HK1045154B/zh not_active IP Right Cessation
- 2002-06-28 HK HK03105903A patent/HK1055293A1/xx not_active IP Right Cessation
-
2003
- 2003-11-07 US US10/703,887 patent/US20040092555A1/en not_active Abandoned
-
2008
- 2008-03-12 CY CY20081100277T patent/CY1107238T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7368574B2 (en) | Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use | |
| OA11871A (en) | Novel pharmaceutical. | |
| US6806280B1 (en) | Polymorph of 5-[4-[2-(n-methyl-n(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione, maleic acid salt | |
| AU771342B2 (en) | Novel pharmaceutical | |
| US7230109B2 (en) | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical | |
| US7358366B2 (en) | Thiazolidinedione derivative and its use as antidiabetic | |
| EP1315721B1 (fr) | Derive de thiazolidinedione et son utilisation comme antidiabetique | |
| US20040038968A1 (en) | Thiazolidinedione derivative and its use as antidiabetic | |
| ZA200108722B (en) | Thiazolidinedione derivative and its use as antidiabetic. |